Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
🇺🇸 What happened to 23andMe? https://t.co/tsHx9U2eiy
23andMe is meeting the same fate that Blackberry, Blockbuster, and Myspace did. The time is now for @nucleusgenomics to change consumer health tech. https://t.co/ileGyBGIWV
The company has never made a profit, according to The Wall Street Journal, since users need to buy a genetics test only once and since attempts to develop a subscriber base and a DNA database for use in pharmaceuticals haven't worked out. https://t.co/sp1PYmU2Iq
Nucleus Genomics has announced its consideration of a public offer to acquire 23andMe, contingent on securing financing and successful negotiations. The proposal aims to revitalize consumer health care. However, the rest of 23andMe's board previously turned down a similar proposal in late July due to the offered price per share of $0.40 and lack of committed funding. 23andMe has struggled financially, never making a profit, as its business model relies on one-time genetics tests and unsuccessful attempts to develop a subscriber base and DNA database for pharmaceuticals.
